Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 6/20 | 0.48 |
| ▸ | ADK | P55263 | 3/20 | 0.46 |
| ▸ | ATG7 | O95352 | 3/20 | 0.45 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.45 |
| ▸ | AMD1 | P17707 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18464362 | 0.77 | ADK (0.57) | HSPA5ADKATG7HSPA8AMD1 | |
| SCHEMBL15746955 | 0.76 | HSPA5 (0.45) | HSPA5ATG7HSPA8RXFP1METTL3 | |
| SCHEMBL19007434 | 0.75 | HSPA5 (0.46) | HSPA5ATG7HSPA8RXFP1 | |
| SCHEMBL6380760 | 0.73 | HSPA8 (0.61) | HSPA5ADKHSPA8RXFP1 | |
| SCHEMBL20419330 | 0.72 | HSPA8 (0.58) | HSPA5HSPA8RXFP1 | |
| SCHEMBL20419169 | 0.72 | HSPA8 (0.58) | HSPA5HSPA8RXFP1 | |
| SCHEMBL1740449 | 0.72 | HSPA5 (0.63) | HSPA5ADKHSPA8RXFP1 | |
| SCHEMBL18464494 | 0.71 | ADK (0.51) | HSPA5ADKATG7HSPA8RXFP1 | |
| SCHEMBL20419157 | 0.70 | HSPA5 (0.61) | HSPA5ADKHSPA8RXFP1 | |
| SCHEMBL16366344 | 0.70 | HSPA5 (0.60) | HSPA5HSPA8AMD1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308283-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | HSPA5 2318/4885ADK 76/4885ATG7 3303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.